Keto and High Cholesterol: What Your NHS Blood Results Actually Mean

Starting low carb and watching your LDL cholesterol climb is one of the most unsettling experiences in this way of eating — particularly when your GP responds by recommending statins. Here’s an honest guide to what’s happening, what the research actually says, and how to navigate it within the NHS.

This isn’t a post that will tell you cholesterol doesn’t matter or that your GP is wrong. The science here is genuinely contested, and anyone telling you it’s all resolved — in either direction — is oversimplifying. What this guide will do is give you the tools to understand your own results and have a more informed conversation.

What a Standard NHS Lipid Panel Tells You

When you have a blood test through your GP, the standard lipid panel reports four things:

• Total cholesterol (TC)
• HDL cholesterol (the so-called “good” cholesterol)
• Triglycerides
• Non-HDL cholesterol (total cholesterol minus HDL — this is increasingly the number NHS clinicians focus on)

LDL cholesterol is usually calculated from these figures rather than measured directly, using the Friedewald equation. This matters because on a very low carb diet — where triglycerides can drop substantially — the equation can produce unreliable LDL estimates. If your triglycerides are very low (below about 0.8 mmol/L), your calculated LDL may be overstated.

All UK results are reported in mmol/L. Most of the research you’ll find online uses mg/dL (the American unit). To convert: divide mg/dL by 38.67 to get mmol/L, or multiply mmol/L by 38.67 to get mg/dL.

How Low Carb Typically Affects the Lipid Panel

The honest picture is that the effect of carbohydrate restriction on cholesterol depends heavily on who you are — specifically, on your starting metabolic health.

In people with Type 2 diabetes, insulin resistance, or obesity

The evidence here is relatively consistent and positive. Multiple systematic reviews and meta-analyses of randomised controlled trials show that low-carbohydrate diets in overweight or insulin-resistant populations tend to:

• Significantly lower triglycerides — often dramatically so
• Raise HDL cholesterol — the marker associated with lower cardiovascular risk
• Have little or no adverse effect on LDL — and sometimes lower it

A 2024 meta-analysis in Frontiers in Nutrition pooling 17 randomised trials and over 1,100 Type 2 diabetes patients found significant improvements in HbA1c, fasting glucose, triglycerides, and HDL, with no statistically significant worsening of LDL.

For people whose elevated cholesterol was driven by insulin resistance and poor metabolic health, low carb frequently improves the picture across the board.

In lean, metabolically healthy people

This is where it gets more complicated. A 2023 meta-analysis by Choi et al. in Clinical Nutrition looked specifically at ketogenic diets in normal-weight adults (BMI under 25) without insulin resistance. The finding: LDL and total cholesterol rose significantly in this group, while triglycerides didn’t change much and HDL improved.

In other words, if you were already metabolically healthy and relatively lean when you started low carb, you’re more likely to see your LDL go up. This is the scenario most people on r/ketouk are worried about.

Why LDL Goes Up in Lean People on Low Carb

The leading mechanistic explanation is called the Lipid Energy Model, developed by researcher Nick Norwitz and citizen scientist Dave Feldman.

The core idea: in lean individuals with limited fat stores and high insulin sensitivity, restricting carbohydrates forces the body to dramatically upregulate fat transport via the bloodstream to fuel peripheral tissues. The liver produces more VLDL (very-low-density lipoprotein) particles loaded with triglycerides. In lean, insulin-sensitive people, these particles are processed efficiently — the triglycerides are rapidly delivered to muscles and other tissues, leaving behind cholesterol-rich LDL particles.

The result is elevated LDL — not because something is going wrong, but as the downstream footprint of a highly active fat-based energy system.

This model predicts something counterintuitive: the leaner and more metabolically healthy you are, the more likely you are to see a large LDL rise on a ketogenic diet. And the data supports this. The people who see LDL jump to 6, 7, 8 mmol/L and beyond on keto tend to be lean, athletic, with excellent HDL and very low triglycerides.

The saturated fat question

Mainstream guidance attributes diet-induced LDL rises primarily to saturated fat intake (which reduces the liver’s ability to clear LDL from the blood). This is a real mechanism. But it’s probably not the only driver in carbohydrate-restricted diets.

A striking illustration: a published case report described a patient whose LDL rose from 2.5 mmol/L to 14 mmol/L on a Mediterranean-style ketogenic diet that was specifically low in saturated fat and high in olive oil and oily fish. His highest LDL readings came while consuming mostly unsaturated fat. When he deliberately gained a small amount of weight — shifting from very lean to merely lean — his LDL actually dropped somewhat. It’s a single case, but it makes the point vividly that energy demand and body composition appear to be significant drivers in their own right.

Not All LDL is the Same

LDL cholesterol is often talked about as a single thing, but LDL particles come in different sizes — and size matters for risk assessment.

Small, dense LDL (sdLDL) particles are more atherogenic. They penetrate the artery wall more easily, stay in circulation longer because the liver doesn’t clear them as efficiently, and are more susceptible to oxidation — the process that turns them into the foam cells at the heart of arterial plaque.

Large, buoyant LDL (lbLDL) particles are cholesterol-rich but clear more easily and appear to be significantly less atherogenic in most of the epidemiological evidence.

The evidence consistently shows that low-carbohydrate diets shift LDL particle distribution toward the larger, more buoyant type. Triglyceride reduction (which consistently occurs on low carb) is closely associated with this shift. A low triglyceride-to-HDL ratio is widely used in metabolic research as a marker of predominantly large, buoyant LDL.

However — and this is important — mainstream European and UK cardiology guidelines take the position that all ApoB-containing particles (which includes all LDL regardless of size) are atherogenic, and that what matters most is the total particle count, not the size distribution. From this perspective, a large rise in LDL-C, even if driven by large buoyant particles, still represents increased cardiovascular risk.

This is a genuine, unresolved scientific disagreement. Both positions have peer-reviewed support. Anyone presenting it as settled — in either direction — isn’t being straight with you.

The Lean Mass Hyper-Responder Phenomenon

The most extreme version of the lean-person LDL response has been given a name: the Lean Mass Hyper-Responder (LMHR) phenotype, coined by Dave Feldman in 2017.

The LMHR triad is:

• LDL ≥ 5.17 mmol/L (200 mg/dL)
• HDL ≥ 2.07 mmol/L (80 mg/dL)
• Triglycerides ≤ 0.79 mmol/L (70 mg/dL)

This specific combination is extremely rare in the general population — appearing in roughly 3 out of every 70,000 people in population databases. But in strict ketogenic diet communities, it may occur in up to 18% of participants. The profile is almost always accompanied by low BMI, high insulin sensitivity, and low inflammatory markers.

What the KETO trial found

The key clinical question — does this massively elevated LDL actually cause arterial plaque in LMHRs? — was directly addressed by the KETO trial, led by cardiologist Dr Matthew Budoff and published in JACC Advances in August 2024.

This prospective study followed 100 LMHR and near-LMHR individuals for one year, using high-resolution coronary CT angiography (CCTA) with AI-assisted plaque analysis to track changes in arterial plaque. The cohort was matched against a control group from the Miami Heart study.

Key findings:

• Despite a median LDL of 6.1 mmol/L (237 mg/dL) in the KETO group, 57% had a coronary artery calcium (CAC) score of zero at baseline
• Over one year, plaque progression was modest and varied considerably between individuals
• Neither LDL levels nor ApoB predicted plaque progression in this cohort — the Bayesian analysis found the data was 6–10 times more consistent with no association than with an association
• The only significant predictor of plaque progression was having plaque already — existing plaque predicted future plaque; circulating ApoB did not
• 15% of participants showed actual plaque regression despite sustaining very high LDL throughout the year

This is remarkable data. It doesn’t prove that high LDL is harmless in all contexts — the mainstream cardiology critique that one year is insufficient to rule out longer-term atherogenesis is legitimate. Cardiovascular disease develops over decades. But it is the first prospective imaging data in this specific population, and it does not support the assumption that LMHR individuals face the same risk from elevated LDL as the general population.

Mainstream cardiology bodies have largely maintained their position: LDL-C is a causal atherogenic factor across all phenotypes, and clinical guidelines don’t carve out exceptions for dietary context. This debate is ongoing.

What UK Clinical Guidelines Say

It’s important to understand the framework your GP is operating within, because they are not free agents — they follow a defined NHS pathway.

NICE guideline NG238 (updated December 2023) is the primary document governing lipid management in the UK. It advises:

• A “cardioprotective diet” with total fat no more than 30% of total energy and saturated fat no more than 7%
• For primary prevention, the goal when starting a statin is a greater than 40% reduction in non-HDL cholesterol
• For secondary prevention (existing CVD), LDL targets of 2.0 mmol/L or below

NG238 does not contain provisions for patients whose LDL has risen due to dietary carbohydrate restriction while other metabolic markers have improved. Your GP is applying a framework that wasn’t designed with this scenario in mind.

HEART UK (the UK’s cholesterol charity) issued a specific statement on ketogenic diets in 2024, citing a meta-analysis of 27 RCTs showing keto increases total cholesterol by a mean of +0.36 mmol/L and LDL by +0.35 mmol/L. They advise healthcare professionals to steer patients away from long-term ketogenic diets on cardiovascular grounds.

The NHS Accelerated Access Collaborative lipid pathway means that if your total cholesterol exceeds 9.0 mmol/L, your LDL exceeds 4.9 mmol/L, or your non-HDL exceeds 7.5 mmol/L, your GP is required by the pathway to suspect Familial Hypercholesterolaemia (FH) — a genetic disorder — and follow up accordingly. If you’re an LMHR, you may meet these thresholds without having FH.

None of this is your GP being obstructive or uninformed. It is the clinical infrastructure doing what clinical infrastructure does: applying evidence-based rules to a population. Your situation may simply be one that the rules weren’t designed for.

What Tests to Ask About

Non-HDL cholesterol

This is already on your standard NHS lipid panel (total cholesterol minus HDL) and is increasingly the primary target in UK clinical practice. Unlike LDL, it captures cholesterol in all atherogenic particles. If your GP is focused on this number, that’s appropriate.

The TG:HDL ratio

You can calculate this yourself from your standard results. Divide your triglycerides by your HDL (both in mmol/L). A ratio below 0.87 mmol/L is generally considered optimal; below 1.74 is acceptable. In research settings, a low TG:HDL ratio is a strong marker of insulin sensitivity and predominantly large, buoyant LDL particles. Your GP may not use this metric, but it’s a useful data point for your own understanding.

ApoB testing

Apolipoprotein B provides a direct count of all atherogenic lipid particles (one ApoB molecule per particle regardless of size). It’s considered a superior marker to LDL-C mass in many metabolic scenarios — particularly where particle size and composition may differ from the norm.

The difficulty: ApoB is not a standard primary care test in the UK. A 2024 joint statement by HEART UK and the Association for Laboratory Medicine acknowledged highly inconsistent use of ApoB across UK labs and called for standardisation. Some GP practices will request it; many won’t or can’t.

If you want ApoB measured and your GP can’t facilitate it, private testing is the practical route. Services like Medichecks, Forth, and Walk-in Clinic all offer ApoB as part of advanced lipid panels at moderate cost. This gives you data to bring to the conversation.

Coronary artery calcium (CAC) scoring

A CAC score uses a low-dose CT scan to measure calcified plaque in your coronary arteries. A score of zero means no detectable calcified plaque and is associated with very low near-term cardiovascular risk — regardless of LDL levels. This isn’t available through NHS primary care for this purpose, but private cardiac screening clinics offer it. It provides the most direct evidence of what is (or isn’t) actually happening in your arteries.

Having the GP Conversation

A few things that may help when your cholesterol results come back elevated:

Bring your full picture. When discussing cholesterol in isolation, the context of your other markers matters. If your triglycerides have dropped significantly, your HDL has risen, your HbA1c has improved, your blood pressure is normal, and you’ve lost weight, say so. Ask your GP to consider your cardiovascular risk profile as a whole, not one number in isolation.

Ask about your non-HDL. This is the number NHS guidance prioritises. If your non-HDL cholesterol is within range despite elevated LDL — which can happen when LDL is driven up by large buoyant particles — that’s worth discussing.

Ask about your TG:HDL ratio. Calculate it before your appointment and ask your GP what they make of it.

Don’t dismiss statins without understanding the context. If you have existing cardiovascular disease, a family history of early heart disease, or other significant risk factors, the calculus around statins is different. The KETO trial data is from lean, metabolically healthy people with no other major risk factors. If that’s not you, the data may not apply to your situation.

Acknowledge the uncertainty. The science here is genuinely unsettled. Going into the conversation with “I understand this is contested and I want to understand my individual risk” is more likely to result in a productive dialogue than arriving with a printed paper insisting your GP is wrong.

The Bottom Line

If your LDL has risen after starting low carb, you’re in a large and growing community of people where the standard cholesterol narrative doesn’t map cleanly onto their experience. The metabolic improvements you may have achieved — lower triglycerides, higher HDL, lower blood sugar, reduced inflammation, weight loss — are cardiovascular risk factors too, and they cut the other way.

At the same time, the mainstream cardiovascular medicine position — that elevated LDL is atherogenic across all contexts and all phenotypes — isn’t irrational. The KETO trial is one year of imaging data from 100 people. It’s important and interesting. It’s not the final word.

The most sensible path is to understand your results fully, get the most informative tests you can access, and have a genuinely informed conversation with your GP rather than either ignoring the numbers or accepting a prescription without engaging with the context.

If you’re seeing very large LDL rises (above 6–7 mmol/L) and you have any other cardiovascular risk factors, please don’t navigate this without medical input. The science may be contested — but the risks are real.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult your GP before making changes to your diet or medication, particularly if you have existing cardiovascular disease, diabetes, or are taking prescribed medication.